Seoul, South Korea, August 5, 2026
Seegene Inc., a global leader in molecular diagnostics, has unveiled a comprehensive PCR-based syndromic diagnostic approach for genital tract infections (RTIs) as part of its Global Million Clinical Study (GMCS). The initiative combines simultaneous detection of human papillomavirus (HPV) and sexually transmitted infection (STI) pathogens, providing clinicians with a more comprehensive understanding of reproductive tract infections through a single molecular test. Using its proprietary STAgoraâ„¢ real-time data analytics platform, Seegene analyzed approximately 60,000 HPV and STI co-test results collected over 42 months, revealing that 82% of HPV-positive cases also tested positive for at least one STI pathogen, while 46% of STI-positive cases were also HPV-positive. The findings highlight the growing importance of integrated molecular diagnostics for improving early disease detection, individualized patient management, and future screening strategies. Through the Global Million Clinical Study, Seegene aims to establish robust clinical evidence supporting comprehensive HPV and STI testing while contributing to the development of next-generation global PCR diagnostic standards.
Global Million Clinical Study Demonstrates Value of Comprehensive Testing
The Global Million Clinical Study (GMCS) represents one of Seegene’s largest international research initiatives designed to collect real-world clinical evidence from healthcare institutions worldwide. The company’s objective is to evaluate disease-specific molecular diagnostic strategies while generating scientific evidence capable of shaping future diagnostic guidelines. Utilizing STAgoraâ„¢, Seegene’s advanced real-time statistical analysis platform, researchers evaluated approximately 60,000 clinical co-testing results involving HPV and STI detection over a 42-month period. Analysis demonstrated a strong relationship between HPV infection and sexually transmitted pathogens, with 71% of positive comprehensive test results showing simultaneous detection of both HPV and STI pathogens. These findings suggest that integrated molecular testing may provide physicians with broader clinical insight than separate testing approaches while improving diagnostic efficiency and supporting more personalized patient care across reproductive health settings.
Integrated PCR Diagnostics Support Earlier Detection and Clinical Decision-Making
Human papillomavirus (HPV) remains the primary cause of cervical cancer, while numerous sexually transmitted infections, including Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, and other reproductive pathogens, often present with overlapping symptoms or remain completely asymptomatic. Because multiple pathogens can produce similar clinical manifestations, accurate diagnosis based solely on symptoms is frequently challenging. Seegene’s multiplex real-time PCR technology enables simultaneous identification of multiple pathogens in a single molecular assay while providing quantitative information that supports physician decision-making. The integrated approach allows clinicians to evaluate HPV genotypes, STI pathogens, reproductive tract infections, patient symptoms, exposure history, fertility planning and previous infections within one comprehensive diagnostic framework. Such detailed molecular information may improve risk assessment, identify previously undetected co-infections and assist physicians in selecting more appropriate patient management strategies.
Advanced Molecular Platforms Strengthen Precision Diagnostics
The announcement reinforces Seegene’s leadership in advancing precision molecular diagnostics through continuous innovation in multiplex PCR, data analytics, and laboratory automation. Building upon more than 25 years of molecular diagnostics expertise, the company continues developing integrated technologies that combine advanced testing solutions with intelligent data platforms. Alongside STAgoraâ„¢, Seegene is expanding development of CURECAâ„¢, its fully automated PCR testing platform designed to streamline the entire molecular diagnostic workflow from sample preparation through result reporting. The company also continues promoting global access to advanced molecular diagnostics through its Technology Sharing Initiative and international collaborations. As evidence from the Global Million Clinical Study continues to expand, Seegene aims to strengthen the scientific foundation supporting comprehensive HPV and STI co-testing, ultimately helping establish new global standards for PCR-based infectious disease diagnostics while improving reproductive healthcare and preventive screening worldwide.
Source: Seegene press release



